Monomethyl auristatin F （MMAF） is a new antimitotic auristatin derivative with a charged C-terminal phenylalanine residue that attenuates its cytotoxic activity compared to its uncharged counterpart MMAE （see references 1 ＆ 2）.
This HRP-MMAF conjugate with a stable thiol ether bond is designed with similar linker chemistry as ADCs prepared by our customer using our Antibody Mc-MMAF Conjugation Kit （Cat#： CM11422）.
This conjugate is synthesized at CellMosaic for the customer's usage in horseradish peroxidase （HRP） based assays.
A long flexible PEG linker is also incorporated in the conjugate to retain the HRP activity and MMAF binding.
The final conjugate is HPLC-purified to obtain 1：1 MMAF-labeled HRP conjugate, and it is lyophilized from PBS containing sugar-based stabilizer for easy shipping and storage.The product is sold as 1 vial of 0.5 mg （Cat# CM53216-0.5MG） or 4 vials of 0.5 mg （Cat# CM53216-2MG）.
